Does tissue transglutaminase play a role in Huntington's disease?

Neurochemistry International

Volumn 40, Issue 1, 2002, Pages 37-52

  Lesort, Mathieu ^a   Chun, WanJoo ^a   Tucholski, Janusz ^a   Johnson, Gail V W ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Huntington's disease; Polyglutamine; Transglutaminase

Indexed keywords

BRAIN ENZYME; HUNTINGTIN; MUTANT PROTEIN; POLYGLUTAMINE; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE;

AMINATION; BRAIN NERVE CELL; CATALYSIS; CELL LEVEL; CONFERENCE PAPER; CROSS LINKING; DISORDERS OF MITOCHONDRIAL FUNCTIONS; ENZYME ACTIVITY; ENZYME LOCALIZATION; ENZYME STRUCTURE; ENZYME SUBSTRATE; HUMAN; HUNTINGTON CHOREA; IMMUNOHISTOCHEMISTRY; NEUROPATHOLOGY; NONHUMAN; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN EXPRESSION; PROTEIN MODIFICATION; PROTEIN PROTEIN INTERACTION; REGULATORY MECHANISM;

ANIMALS; HUMANS; HUNTINGTON DISEASE; NERVE TISSUE PROTEINS; NUCLEAR PROTEINS; PEPTIDES; PROTEIN STRUCTURE, TERTIARY; TRANSGLUTAMINASES;

EID: 0036134809     PISSN: 01970186     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0197-0186(01)00059-6     Document Type: Conference Paper

References (121)

1. Identification of a guanosine triphosphate-binding site on guinea pig liver transglutaminase. Role of GTP and calcium ions in modulating activity
2. Transglutaminase-catalyzed matrix cross-linking in differentiating cartilage: Identification of osteonectin as a major glutaminyl substrate
3. Isolation of a cDNA encoding a novel member of the transglutaminase gene family from human keratinocytes. Detection and identification of transglutaminase gene products based on reverse transcription-polymerase chain reaction with degenerate primers
4. Tissue transglutaminase and factor XIII in cartilage and bone remodeling
5. Transglutaminases: Protein cross-linking enzymes in tissues and body fluids
6. Alternative excitotoxic hypotheses
7. 3-Nitropropionate, the toxic substance of Indigofera, is a suicide inactivator of succinate dehydrogenase
8. Huntington's disease, energy, and excitotoxicity
9. Mitochondria, free radicals, and neurodegeneration
10. Neurochemical and histologic characterization of striatal excitotoxic lesions produced by the mitochondrial toxin 3-nitropropionic acid
11. 3-Nitropropionic acid neurotoxicity is attenuated in copper/zinc superoxide dismutase transgenic mice
12. Intranuclear neuronal inclusions in Huntington's disease and dentatorubral and pallidoluysian atrophy: Correlation between the density of inclusions and IT15 CAG triplet repeat length
13. Covalent incorporation of polyamines as γ-glutamyl derivatives into CHO cell protein
14. Positron emission tomographic scan investigations of Huntington's disease: Cerebral metabolic correlates of cognitive function
15. Cellular transglutaminase, growth, and transformation
16. Aberrant interactions of transcriptional repressor proteins with the Huntington's disease gene product, huntingtin
17. Effects of chronic MPTP and 3-nitropropionic acid in non human primates
18. Chronic mitochondrial energy impairment produces selective striatal degeneration and abnormal choreiform movements in primates
19. Oxidative damage and metabolic dysfunction in Huntington's disease: Selective vulnerability of the basal ganglia
20. Distribution of phosphate-activated glutaminase, succinic dehydrogenase, pyruvate dehydrogenase and γ-glutamyl transpeptidase in post-mortem brain from Huntington's disease and agonal cases
21. Two types of transglutaminase in the PC12 pheochromocytoma cell line. Stimulation by sodium butyrate
22. Transglutaminase activity is related to CAG repeat length in patients with Huntington's disease
23. Post-translational protein modification by polyamines in intact and regenerating nerves
24. Mutant huntingtin associated proteins are selectively modified by tissue transglutaminase (tTG) only in truncated huntingtin expressing cells in situ
25. Tissue transglutaminase does not contribute to the formation of mutant huntingtin aggregates
26. Tissue transglutaminase selectively modifies proteins associated with truncated mutant huntingtin in situ
27. Inactivation of succinate dehydrogenase by 3-nitropropionate
28. Polyglutamine domains are substrates of tissue transglutaminase: Does transglutaminase play a role in expanded CAG/poly-Q neurodegenerative diseases?
29. Pathogenesis of inclusion bodies in (CAG)n/Qn-expansion diseases with special reference to the role of tissue transglutaminase and to selective vulnerability
30. Transglutaminase-catalyzed incorporation of polyamines into phospholipase A2
31. Mutation of the E6-AP ubiquitin ligase reduces nuclear inclusion frequency while accelerating polyglutamine-induced pathology in SCA1 mice
32. Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation
33. The length of polyglutamine tract, its level of expression, the rate of degradation, and the transglutaminase activity influence the formation of intracellular aggregates
34. Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain
35. Tissue specific and androgen-regulated expression of human prostate-specific transglutaminase
36. Extracellular-regulated kinases and phosphatidylinositol 3-kinase are involved in brain-derived neurotrophic factor-mediated survival and neuritogenesis of the neuroblastoma cell line SH-SY5Y
37. Effect of exogenous and endogenous antioxidants on 3-nitropionic acid-induced in vivo oxidative stress and striatal lesions: Insights into Huntington's disease
38. Isolation and characterization of cDNA clones to mouse macrophage and human endothelial cell tissue transglutaminases
39. Tissue transglutaminase-catalyzed formation of high-molecular-weight aggegates in vitro is favored with long polylglutamine domains: A possible mechanism contributing to CAG-triplet diseases
40. Juvenile Huntington chorea: Clinical, ultrastructural, and biochemical studies
41. Molecular cloning and characterization of a novel transglutaminase cDNA from a human prostate cDNA library
42. Human genetic diseases due to codon reiteration: Relationship to an evolutionary mechanism
43. Transglutaminases: Multifunctional cross-linking enzymes that stabilize tissues
44. Exposure of beta H-crystallin to hydroxyl radicals enhances the transglutaminase-susceptibility of its existing amine-donor and amine-acceptor sites
45. Molecular genetics of Huntington's disease
46. Nuclear and neuropil aggregates in Huntington's disease: Relationship to neuropathology
47. Activation of transglutaminase at calcium levels consistent with a role for this enzyme as a calcium receptor protein
48. Cellular transglutaminases in neural development
49. Molecular cloning of rat prostate transglutaminase complementary DNA. The major androgen-regulated protein DP1 of rat dorsal prostate and coagulating gland
50. Suppression of aggregate formation and apoptosis by transglutaminase inhibitors in cells expressing truncated DRPLA protein with an expanded polyglutamine stretch
51. The core domain of the tissue transglutaminase Gh hydrolyzes GTP and ATP
52. Identification of amine acceptor protein substrates of transglutaminase in liver extracts: Use of 5-(biotinamido) pentylamine as a probe
53. Amino acid sequence of guinea pig liver transglutaminase from its cDNA sequence
54. Transglutaminase II: A new class of GTP-binding protein with new biological functions
55. Transglutaminase activity is increased in Alzheimer's disease brain
56. Transglutaminase action imitates Huntington's disease: Selective polymerization of Huntingtin containing expanded polyglutamine
57. Peptides containing glutamine repeats as substrates for transglutaminase-catalyzed cross-linking: Relevance to diseases of the nervous
58. Transglutaminase aggregates huntingtin into nonamyloidogenic polymers, and its enzymatic activity increases in Huntington's disease brain nuclei
59. The complete amino acid sequence of the human transglutaminase K enzyme deduced from the nucleic acid sequences of cDNA clones
60. Mutant huntingtin expression in clonal striatal cells: Dissociation of inclusion formation and neuronal survival by caspase inhibition
61. The structure of the transglutaminase 1 enzyme. Deletion cloning reveals domains that regulate its specific activity and substrate specificity
62. Ataxin-1 nuclear localization and aggregation: Role in polyglutamine-induced disease in SCA1 transgenic mice
63. Chaperones Hsp70 and Hsp40 suppress aggregate formation and apoptosis in cultured neuronal cells expressing truncated androgen receptor protein with expanded polyglutamine tract
64. Bovine aortic endothelial cell transglutaminase. Enzyme characterization and regulation of activity
65. Organization of the gene for human erythrocyte membrane protein 4.2: Structural similarities with the gene for the a subunit of factor XIII
66. Huntington aggregates may not predict neuronal death in Huntington's disease
67. Cortical and subcortical glucose consumption measured by PET in patients with Huntington's disease
68. Carboxyl-terminal truncation of recombinant factor XIII A-chains. Characterization of minimum structural requirement for transglutaminase activity
69. Sphingosylphosphocholine reduces the calcium ion requirement for activating tissue transglutaminase
70. Regulation of human tissue transglutaminase function by magnesium-nucleotide complexes. Identification of distinct binding sites for Mg-GTP and Mg-ATP
71. Site-directed mutagenesis of human tissue transglutaminase: Cys-277 is essential for transglutaminase activity but not for GTPase activity
72. Distinct nuclear localization and activity of tissue transglutaminase
73. Tissue transglutaminase is increased in Huntington's disease brain
74. Tissue transglutaminase: A possible role in neurodegenerative diseases
75. Impaired mitochondrial function results in increased tissue transglutaminase activity in situ
76. DRPLA aggregation and transglutaminase, revisited
77. Transglutaminases
78. Transglutaminase and neuronal differentiation
79. Cortical glucose metabolism in Huntington's disease
80. CREB-binding protein sequestration by expanded polyglutamine
81. Transglutaminase and the neuronal cytoskeleton in Alzheimer's disease
82. Transglutaminase cross-linking of the tau protein
83. Polyamines in human brain: Regional distribution and influence of aging
84. Cloning and sequence analysis of cDNA clones for bovine aortic-endothelial-cell transglutaminase
85. Gh: A GTP-binding protein with transglutaminase activity and receptor signaling function
86. Identification of cytoplasmic actin as an abundant glutaminyl substrate for tissue transglutaminase in HL-60 and U937 cells undergoing apoptosis
87. Ectopically expressed CAG repeats cause intranuclear inclusions and a progressive late onset neurological phenotype in the mouse
88. Modulation of carbachol-stimulated AKP-1 DNA binding by bipolar therapeutic agents in human neuroblastoma SH-SY5Y cells
89. Chronic 3-nitropropionic acid treatment in baboons replicates the cognitive and motor deficits of Huntington's disease
90. Recruitment and the role of nuclear localization in polyglutamine-mediated aggregation
91. Localization and activity of transglutaminase, a retinoid-inducible protein, in developing rat spinal cord
92. Transglutaminase C in cerebellar granule neurons: Regulation and localization of substrate cross-linking
93. Polar zippers: Their role in human disease
94. Glutamine repeats as polar zippers: Their possible role in inherited neurodegenerative diseases
95. Primary structure of keratinocyte transglutaminase
96. Free and protein-conjugated polyamines in mouse epidermal cells. Effect of high calcium and retinoic acid
97. Identification of 'tissue' transglutaminase binding proteins in neural cells committed to apoptosis
98. Identification of a band-3 binding site near the N-terminus of erythrocyte membrane protein 4.2
99. Huntingtin acts in the nucleus to induce apoptosis but death does not correlate with the formation of intranuclear inclusions
100. Increased apoptosis of Huntington disease lymphoblasts associated with repeat length-dependent mitochondrial depolarization
101. Involvement of oxidative stress in 3-nitropropionic acid neurotoxicity
102. Brain transglutaminase: In vitro crosslinking of human neurofilament proteins into insoluble polymers
103. Expanded polyglutamine stretches interact with TAFII130, interfering with CREB-dependent transcription
104. Identification and biochemical characterization of an 80 kilodalton GTP- binding/transglutaminase from rabbit liver nuclei
105. Subcellular localization of a membrane-associated transglutaminase activity in rat liver
106. 2+ and nucleotides
107. The Huntington's disease protein interacts with p53 and CREB-binding protein and represses transcription
108. Putative nucleotide binding sites of guinea pig liver transglutaminase
109. Studies on brain biopsies of patients with Huntington's chorea
110. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes
111. Tau is modified by tissue transglutaminase in situ: Possible functional and metabolic effects of polyamination
112. Tissue transglutaminase is essential for neurite outgrowth in human neuroblastoma SH-SY5Y cells
113. Differential expression of ubiquitous and neuronal kinesin heavy chains during differentiation of human neuroblastoma and PC12 cells
114. Huntington disease
115. Caspase cleavage of gene products associated with triplet expansion disorders generates truncated fragments containing the polyglutamine tract
116. Inhibiting caspase cleavage of huntingtin reduces toxicity and aggregate formation in neuronal and nonneuronal cells
117. Cloning and expression of chicken erythrocyte transglutaminase
118. Homozygotes for Huntington's disease
119. Effects of heat shock, heat shock protein 40 (HDJ-2), and proteasome inhibition on protein aggregation in cellular models of Huntington's disease
120. Tissue transglutaminase is an in situ substrate of calpain: Regulation of activity
121. Modulation of the in situ activity of tissue transglutaminase by calcium and GTP